Loading clinical trials...
Loading clinical trials...
Multicenter, Randomized, Double-blind, Parallel-group, add-on, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)
Conditions
Interventions
Ponesimod
Placebo
Locations
119
United States
UAB Dpt of Neurology
Birmingham, Alabama, United States
Neuro-Pain Medical Center
Fresno, California, United States
SC3 Research - Pasadena
Pasadena, California, United States
Care Access Research - Santa Clarita
Santa Clarita, California, United States
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, California, United States
University of Colorado Hospital
Aurora, Colorado, United States
Start Date
March 30, 2017
Primary Completion Date
March 26, 2020
Completion Date
March 26, 2020
Last Updated
May 18, 2021
NCT07325292
NCT05748015
NCT06433765
NCT07466823
NCT04876339
NCT05344469
Lead Sponsor
Actelion
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions